Primary synchronous small and non-small cell lung cancer in the same lung lobe: A case report

Dzian, Anton; Fučela, Ivan; Huťka, Zdenko; Szépe, P

doi:10.4081/monaldi.2017.797

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 The combination of SCLC and adenocarcinoma is a relatively rare cases. [7][8][9] Our patient had a high initial NSE value of 36.9 ng/mL (<16. Presently, ICIs and chemotherapy combination treatment can be used as primary treatment for advanced non-SCLC (NSCLC).…”

Section: Discussionmentioning

confidence: 76%

See 1 more Smart Citation

Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report

et al. 2020

View full text Add to dashboard Cite

Background: Combination immune checkpoint inhibitor (ICI) therapy has become the mainstay in cancer treatment, and the various antitumor effects of ICIs are being observed. Synchronous multiple primary lung cancers (SMPLCs), which simultaneously involve tumors of different histologies, are often encountered in clinical settings. In standard lung cancer treatment, an anticancer drug, usually a platinum-based drug, is administered, and this first treatment provides some antitumor effect. Thus, the initial administration of platinum-based anticancer agent may mask the detection of SMPLCs. The following case represents different antitumor effects on two different primary lung lesions during treatment with ICIs. Case presentation: A 72-year-old man was referred to our hospital for an abnormal chest shadow, and computed tomography showed masses in the left lower and right upper lungs. Transbronchial lung biopsy from the left lung tumor revealed an adenocarcinoma. Following the administration of pembrolizumab (200 mg/body over 3 weeks) as monotherapy, the tumor in the left lung rapidly reduced in size. However, the tumor in the right upper lung continued to grow. Finally, his disease was diagnosed as SMPLCs of adenocarcinoma and small cell lung cancer. Conclusion: Bilateral lung lesions considered to be intrapulmonary metastases have completely different responses to ICI treatment. It is necessary to consider a diagnosis of SMPLCs if lesions with different responses to antitumor therapy are observed.

show abstract

Section: Discussionmentioning

confidence: 76%

“…Many SMPLCs have been reported in combination with Non‐small cell lung cancer 6 . The combination of SCLC and adenocarcinoma is a relatively rare cases 7‐9 …”

Section: Discussionmentioning

confidence: 99%

Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Lipid peroxides are biosynthesised by oxidising of polyunsaturated fatty acids, which are unstable and disintegrate to form a complex series of compounds [9]. These include reactive carbonyl compounds; the most abundant compound is malondialdehyde [10]. MDA attacks the lysine amino acid in protein which leads to proteolysis.…”

Section: Introductionmentioning

confidence: 99%

Estimation of Nitric Oxide, Malondialdehyde, and Adenosine Deaminase in Serum of Hypertensive Patients and Normotensive Individuals in Erbil City

Ibrahim¹,

Abdulkareem²,

Hasan³

2019

Tikrit J. Pure Sci.

View full text Add to dashboard Cite

This study was aimed to estimate nitric oxide (NO), malondialdehyde (MDA), and adenosine deaminase (ADA) in the serum of hypertensive patients. Fifty patients (25 males and 25 females) age 40-70 diagnosed with hypertension involved in the study. Fifty healthy individuals, who had no hypertension in the last year, were identified as the control group. NO, MDA and ADA have performed accordingly. MDA was higher with aging and gender in hypertensive patients. Serum level of MDA was higher in females compared with male due to oxidative stress more in female than a male with aging. ADA was higher among hypertensive with aging, though no significant differences among gender. Serum level of NO was lower with aging with no significant differences among gender.

show abstract

Synchronous lung cancer presenting with small cell carcinoma and squamous cell lung carcinoma: a case report

Stirpe,

Bardaro,

Koehl

2023

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Synchronous multiple primary lung cancers are separate tumors presenting at the same time with different histology. We present a rare case of a 64-year-old patient with a combination of small-cell lung carcinoma (SCLC) and squamous carcinoma in two different sites with metastasis of SCLC in the mediastinal lymph node. The SCLC diagnosis was performed via bronchoscopy, and the other diagnosis via CT-guided transthoracic biopsy. It is often difficult to distinguish a synchronous tumor from intrapulmonary metastases. To date, there are no guidelines for the treatment of these cases. The management of synchronous multiple primary lung cancer (SMPLC), mainly surgical with chemotherapy or radiotherapy, must be studied according to the histological type, staging and molecular testing of the tumors. These rare cases of SMPLC require individual treatment and a multidisciplinary approach.

show abstract

Primary synchronous small and non-small cell lung cancer in the same lung lobe: A case report

Cited by 3 publications

References 7 publications

Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report

Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report

Estimation of Nitric Oxide, Malondialdehyde, and Adenosine Deaminase in Serum of Hypertensive Patients and Normotensive Individuals in Erbil City

Synchronous lung cancer presenting with small cell carcinoma and squamous cell lung carcinoma: a case report

Contact Info

Product

Resources

About